<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512185</url>
  </required_header>
  <id_info>
    <org_study_id>15-9075</org_study_id>
    <nct_id>NCT02512185</nct_id>
  </id_info>
  <brief_title>Towards Optimal Prescription of Chemotherapy in Prostate Cancer</brief_title>
  <acronym>TOPCOP</acronym>
  <official_title>TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Cancer Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the impact of modern treatments for metastatic Castrate Resistant
      Prostate Cancer (mCRPC) on several relevant 'geriatric' domains such as daily function,
      objective physical function, and falls. Additionally, the investigators study whether frailty
      is associated with worse outcomes, and whether it is possible to predict the risk of severe
      chemotherapy toxicity in older men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary aims are (a) to examine the impact of pre-treatment frailty on 'elder-relevant'
      outcomes including daily function, objective physical function, falls, quality of life (QOL),
      and early treatment discontinuation; (b) to determine whether the Hurria/Cancer and Aging
      Research Group (CARG) tool is able to predict severe (grade 3+) chemotherapy toxicity in men
      starting chemotherapy. Our secondary aim is to understand the impact of abiraterone and
      enzalutamide on 'elder-relevant' outcomes.

      This is a prospective multicentre observational study. The investigators will enroll men age
      65 or older with mCRPC who are starting (a) first-line chemotherapy; (b) abiraterone; or (c)
      enzalutamide. Assessments will occur prior to starting treatment and every 2 months
      thereafter until the end of treatment.

      As treatment options become more complex in older men with mCRPC, understanding and
      predicting a wide range of treatment toxicities is important and will aid decision-making and
      management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Daily function assessed by questionnaires</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Daily function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective physical function</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Will be assessed by 3 physical performance measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3+ toxicity using Common Terminology Criteria for Adverse Events (CTC-AE) version 4.0</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of falls provided by the participant</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Falls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body fat percentage will be measured using a Tanita 300A analyzer</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Body composition analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>FACT-G and FACT-P (specific for prostate cancer) questionnaires will be administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Montreal Cognitive Assessment (MoCA test) and Trail making tests A&amp;B</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Cognition composite</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <description>Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone</arm_group_label>
    <description>Men with mCRPC starting Abiraterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <description>Men with mCRPC starting Enzalutamide</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Men 65 and older starting first line chemotherapy, or Abiraterone, or Enzalutamide for
        mCRPC
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 65 years of age

          2. Diagnosed with prostate cancer with evidence of clinical and/or radiographic evidence
             of progression despite adequate androgen deprivation therapy and achievement of
             castration (total testosterone level &lt;1.7 nmol/L measured within 6 months of
             enrollment)

          3. Among men starting either abiraterone or enzalutamide, no prior
             chemotherapy/abiraterone/enzalutamide. Among men starting first-line chemotherapy,
             commencing docetaxel but can have had either prior abiraterone or enzalutamide

        Exclusion Criteria:

          1. Unable to speak English fluently.

          2. Severe neuropsychiatric abnormalities that prevent study participation.

          3. Limited life expectancy (&lt;3 months) as estimated by the primary oncologist.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Henriette Breunis</last_name>
    <phone>416-946-4501 ext. 3926</phone>
    <email>hbreunis@uhnresearch.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Hotte, MD</last_name>
      <phone>905-387- 9711</phone>
      <phone_ext>64605</phone_ext>
      <email>sebastien.hotte@jcc.hhsc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre -KGH</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Lindsay</last_name>
      <phone>: 613-549-6666</phone>
      <phone_ext>7231</phone_ext>
      <email>Carrie.Lindsay@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Gregg, MD., FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urban Emmenegger, MD</last_name>
      <phone>416-480-4928</phone>
      <email>urban.emmenegger@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Scott Berry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henriette Breunis</last_name>
      <phone>+1-416-946-4501</phone>
      <phone_ext>3926</phone_ext>
      <email>hbreunis@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Shabbir Alibhai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Joshua, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aaron Hansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>April 21, 2018</last_update_submitted>
  <last_update_submitted_qc>April 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>mCRPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

